Diagnostic imaging agent developer Lantheus Medical Imaging has renewed its long-term agreement with Fujifilm RI Pharma (FRI) to license and distribute the Cardiolite and Neurolite pharmaceuticals in Japan.
Under the terms of the 10-year agreement, effective January 1, Lantheus will continue to supply FRI with Cardiolite and Neurolite in finished form and provide the raw materials to manufacture and sell the products in unit dose form. The agreement immediately follows an earlier 10-year pact with Fuji.
Cardiolite and Neurolite are technetium-based radiopharmaceutical imaging agents used in SPECT imaging.
